New Delhi [India], July 29 (ANI): The Union health ministry made the biggest allocation of hydroxychloroquine (HCQ) tablets since the beginning of the COVID-19 pandemic in India by distributing 4.24 crore medicines to the states and Union Territories.
HCQ is an anti-malarial drug that is also used to treat other autoimmune diseases. Currently, the drug is being used for the treatment of COVID-19 patients and is recommended as a prophylaxis of the virus as per the national taskforce for COVID-19.
"Last Saturday, the government made the biggest allotment order for distribution of 4.24 crore HCQ drugs to the states and Union Territories for their use. This is the largest distribution so far since the beginning of the virus pandemic. States have to use these HCQ tablets for the treatment of COVID-19 patients and as prophylaxis," informed a senior health ministry official.
He added that the previous allocations were smaller and done as per the requirement of the states. He also informed that the government has a huge buffer stock of HCQ, and hence such allocations are being done.
According to the clinical management protocol for COVID-19, the HCQ has been described as 'repurposed or off-label therapy.' It has also been noted that HCQ has demonstrated in vitro activity against SARS-CoV2 and was shown to be clinically beneficial in several small single centre studies, though with significant limitations.
"This drug (HCQ) should be used as early in the disease course as possible to achieve any meaningful effects and should be avoided in patients with severe disease. An ECG should ideally be done before prescribing the drug to measure QTc interval (and HCQ avoided if QTc is >500 ms). The dose should be given 400 mg twice on day 1 followed by 400mg daily for the next 4 days," stated clinical management protocol for COVID-19.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)